247 related articles for article (PubMed ID: 18334972)
1. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
[TBL] [Abstract][Full Text] [Related]
2. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.
Lin CY; Chao A; Wang TH; Hsueh S; Lee YS; Wu TI; Chao AS; Huang HJ; Chou HH; Chang TC; Lai CH
J Mol Med (Berl); 2014 Sep; 92(9):969-81. PubMed ID: 24820961
[TBL] [Abstract][Full Text] [Related]
3. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
[TBL] [Abstract][Full Text] [Related]
4. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
6. EGFR and HER2 inhibition in pancreatic cancer.
Walsh N; Kennedy S; Larkin A; Corkery B; O'Driscoll L; Clynes M; Crown J; O'Donovan N
Invest New Drugs; 2013 Jun; 31(3):558-66. PubMed ID: 23076814
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
9. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Sambade MJ; Kimple RJ; Camp JT; Peters E; Livasy CA; Sartor CI; Shields JM
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):575-81. PubMed ID: 20457354
[TBL] [Abstract][Full Text] [Related]
13. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Kim HP; Yoon YK; Kim JW; Han SW; Hur HS; Park J; Lee JH; Oh DY; Im SA; Bang YJ; Kim TY
PLoS One; 2009 Jun; 4(6):e5933. PubMed ID: 19529774
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
17. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
19. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
20. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]